Review



high-throughput protein microarray huprot tm v4.0  (CDI Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    CDI Laboratories high-throughput protein microarray huprot tm v4.0
    Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; <t>HuProt</t> TM , Human Proteome <t>Microarray;</t> ELISA, enzyme-linked immunosorbent assay.
    High Throughput Protein Microarray Huprot Tm V4.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/high-throughput+protein+microarray+huprot+tm+v4%2E0/pmc12032526-175-1-10?v=CDI+Laboratories
    Average 90 stars, based on 1 article reviews
    high-throughput protein microarray huprot tm v4.0 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules"

    Article Title: A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules

    Journal: Genomics, Proteomics & Bioinformatics

    doi: 10.1093/gpbjnl/qzae085

    Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; HuProt TM , Human Proteome Microarray; ELISA, enzyme-linked immunosorbent assay.
    Figure Legend Snippet: Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; HuProt TM , Human Proteome Microarray; ELISA, enzyme-linked immunosorbent assay.

    Techniques Used: Control, Microarray, Enzyme-linked Immunosorbent Assay

    Profiling of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control in the HuProt TM screening The heatmap displays a distinct distribution of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control, with generally higher levels of IgM observed in Early-LUAD. All values are normalized. The plots on the top display the data on age, sex, smoking, and alcohol consumption for each group, while the bar chart on the right side shows the sensitivity of each autoantibody. Control indicates the BLD+NHC group.
    Figure Legend Snippet: Profiling of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control in the HuProt TM screening The heatmap displays a distinct distribution of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control, with generally higher levels of IgM observed in Early-LUAD. All values are normalized. The plots on the top display the data on age, sex, smoking, and alcohol consumption for each group, while the bar chart on the right side shows the sensitivity of each autoantibody. Control indicates the BLD+NHC group.

    Techniques Used: Control

    Verification of autoantibodies by focused microarray A . Repeated detection of pooled samples displayed high reproducibility, with an averaged correlation coefficient of 0.95. Pooled samples comprised randomly selected samples from the Early-LUAD, BLD, and NHC groups (10 samples in each group). ***, P < 0.001 ( t -test for Pearson correlation coefficients). B . The top 10/top 15 IgG and IgM autoantibodies with the most significant elevation in Early-LUAD compared to BLD/NHC/Control are displayed. These most significant autoantibodies are ranked based on their FC on the vertical axis and sensitivity on the horizontal axis. C . A descending trend in the signal distribution of IgM autoantibodies across three representative samples from the Early-LUAD, BLD, and NHC groups, respectively. The images on the left visually depict the functionality of the focused microarray, while the 3D bar plots on the right show the distribution of normalized fluorescence intensities. D . IgG and IgM types of autoantibodies showed significantly higher levels in Early-LUAD compared to BLD. *, P < 0.05; **, P < 0.01 (Welch’s t -test). FC, fold change; NS, not significant.
    Figure Legend Snippet: Verification of autoantibodies by focused microarray A . Repeated detection of pooled samples displayed high reproducibility, with an averaged correlation coefficient of 0.95. Pooled samples comprised randomly selected samples from the Early-LUAD, BLD, and NHC groups (10 samples in each group). ***, P < 0.001 ( t -test for Pearson correlation coefficients). B . The top 10/top 15 IgG and IgM autoantibodies with the most significant elevation in Early-LUAD compared to BLD/NHC/Control are displayed. These most significant autoantibodies are ranked based on their FC on the vertical axis and sensitivity on the horizontal axis. C . A descending trend in the signal distribution of IgM autoantibodies across three representative samples from the Early-LUAD, BLD, and NHC groups, respectively. The images on the left visually depict the functionality of the focused microarray, while the 3D bar plots on the right show the distribution of normalized fluorescence intensities. D . IgG and IgM types of autoantibodies showed significantly higher levels in Early-LUAD compared to BLD. *, P < 0.05; **, P < 0.01 (Welch’s t -test). FC, fold change; NS, not significant.

    Techniques Used: Microarray, Control, Fluorescence



    Similar Products

    high-throughput protein microarray huprot tm v4.0  (CDI Laboratories)
    90
    CDI Laboratories high-throughput protein microarray huprot tm v4.0
    Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; <t>HuProt</t> TM , Human Proteome <t>Microarray;</t> ELISA, enzyme-linked immunosorbent assay.
    High Throughput Protein Microarray Huprot Tm V4.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/high-throughput+protein+microarray+huprot+tm+v4%2E0/pmc12032526-175-1-10?v=CDI+Laboratories
    Average 90 stars, based on 1 article reviews
    high-throughput protein microarray huprot tm v4.0 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; HuProt TM , Human Proteome Microarray; ELISA, enzyme-linked immunosorbent assay.

    Journal: Genomics, Proteomics & Bioinformatics

    Article Title: A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules

    doi: 10.1093/gpbjnl/qzae085

    Figure Lengend Snippet: Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; HuProt TM , Human Proteome Microarray; ELISA, enzyme-linked immunosorbent assay.

    Article Snippet: The high-throughput protein microarray HuProt TM v4.0 was obtained from CDI Laboratories (Catalog No. CDIHP-004, Baltimore, MD).

    Techniques: Control, Microarray, Enzyme-linked Immunosorbent Assay

    Profiling of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control in the HuProt TM screening The heatmap displays a distinct distribution of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control, with generally higher levels of IgM observed in Early-LUAD. All values are normalized. The plots on the top display the data on age, sex, smoking, and alcohol consumption for each group, while the bar chart on the right side shows the sensitivity of each autoantibody. Control indicates the BLD+NHC group.

    Journal: Genomics, Proteomics & Bioinformatics

    Article Title: A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules

    doi: 10.1093/gpbjnl/qzae085

    Figure Lengend Snippet: Profiling of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control in the HuProt TM screening The heatmap displays a distinct distribution of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control, with generally higher levels of IgM observed in Early-LUAD. All values are normalized. The plots on the top display the data on age, sex, smoking, and alcohol consumption for each group, while the bar chart on the right side shows the sensitivity of each autoantibody. Control indicates the BLD+NHC group.

    Article Snippet: The high-throughput protein microarray HuProt TM v4.0 was obtained from CDI Laboratories (Catalog No. CDIHP-004, Baltimore, MD).

    Techniques: Control

    Verification of autoantibodies by focused microarray A . Repeated detection of pooled samples displayed high reproducibility, with an averaged correlation coefficient of 0.95. Pooled samples comprised randomly selected samples from the Early-LUAD, BLD, and NHC groups (10 samples in each group). ***, P < 0.001 ( t -test for Pearson correlation coefficients). B . The top 10/top 15 IgG and IgM autoantibodies with the most significant elevation in Early-LUAD compared to BLD/NHC/Control are displayed. These most significant autoantibodies are ranked based on their FC on the vertical axis and sensitivity on the horizontal axis. C . A descending trend in the signal distribution of IgM autoantibodies across three representative samples from the Early-LUAD, BLD, and NHC groups, respectively. The images on the left visually depict the functionality of the focused microarray, while the 3D bar plots on the right show the distribution of normalized fluorescence intensities. D . IgG and IgM types of autoantibodies showed significantly higher levels in Early-LUAD compared to BLD. *, P < 0.05; **, P < 0.01 (Welch’s t -test). FC, fold change; NS, not significant.

    Journal: Genomics, Proteomics & Bioinformatics

    Article Title: A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules

    doi: 10.1093/gpbjnl/qzae085

    Figure Lengend Snippet: Verification of autoantibodies by focused microarray A . Repeated detection of pooled samples displayed high reproducibility, with an averaged correlation coefficient of 0.95. Pooled samples comprised randomly selected samples from the Early-LUAD, BLD, and NHC groups (10 samples in each group). ***, P < 0.001 ( t -test for Pearson correlation coefficients). B . The top 10/top 15 IgG and IgM autoantibodies with the most significant elevation in Early-LUAD compared to BLD/NHC/Control are displayed. These most significant autoantibodies are ranked based on their FC on the vertical axis and sensitivity on the horizontal axis. C . A descending trend in the signal distribution of IgM autoantibodies across three representative samples from the Early-LUAD, BLD, and NHC groups, respectively. The images on the left visually depict the functionality of the focused microarray, while the 3D bar plots on the right show the distribution of normalized fluorescence intensities. D . IgG and IgM types of autoantibodies showed significantly higher levels in Early-LUAD compared to BLD. *, P < 0.05; **, P < 0.01 (Welch’s t -test). FC, fold change; NS, not significant.

    Article Snippet: The high-throughput protein microarray HuProt TM v4.0 was obtained from CDI Laboratories (Catalog No. CDIHP-004, Baltimore, MD).

    Techniques: Microarray, Control, Fluorescence